GlassScriptPhysician profile
Philip Jr Mccarthy
NPI 1770574808
$76,398.20
in general payments reported to CMS, 2019-2025
16 companies · $5,550 in 2025
The $5,550 reported for 2025 was more than what 83% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42K · 2020: $10K · 2021: $3,756 · 2022: $2,400 · 2023: $4,537 · 2024: $8,281 · 2025: $5,550.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $16K · Travel and Lodging: $1,031 · Food and Beverage: $950 · Education: $37.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $16,350.00 |
| Travel and Lodging | $1,030.50 |
| Food and Beverage | $950.00 |
| Education | $37.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $19,050.10 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $13,905.21 | 2019-2025 | Abecma |
| Takeda Pharmaceuticals U.S.A., INC. | $12,859.15 | 2019-2020 | |
| Hikma Pharmaceuticals USA | $8,130.00 | 2019 | |
| Karyopharm Therapeutics INC. | $5,595.00 | 2020 | |
| Beigene USA, INC. | $4,500.00 | 2023 | |
| Genentech, INC. | $3,014.67 | 2019 | |
| Glaxosmithkline, LLC. | $2,400.00 | 2022 | |
| Novartis Pharmaceuticals Corporation | $2,358.00 | 2021 | |
| Partner Therapeutics, INC. | $2,298.00 | 2020 | |
| Janssen Global Services, LLC | $2,161.03 | 2019 | |
| Kite Pharma, INC. | $87.61 | 2019 | |
| Legend Biotech USA INC. | $25.50 | 2024 | |
| Acrotech Biopharma INC. | $13.93 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Mccarthy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.